Compare Sibanye Stillwater Ltd (SBSW) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sibanye Stillwater Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? Sibanye Stillwater Ltd trades at $8.59 (market cap $5.66B), while State Street SPDR S&P Biotech ETF trades at $154.49. The key difference: Sibanye Stillwater Ltd pays a 3.89% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Sibanye Stillwater Ltd nearer its low. Which is the better fit depends on your goals.
| SBSW | XBI | |
|---|---|---|
Market Cap | $5.66B | — |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $21.12 | $164.28 |
52-Week Low | $7.27 | $85.16 |
Enterprise Value | $7.28B | — |
Dividend Yield | 3.89% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
